Targeting of Radioactive Platinum-Bisphosphonate Anticancer Drugs to Bone of High Metabolic Activity

Scientific Reports - United Kingdom
doi 10.1038/s41598-020-62039-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

A Copper Connection to the Uptake of Platinum Anticancer Drugs

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2002English

Metabolic Monosaccharides Altered Cell Responses to Anticancer Drugs

European Journal of Pharmaceutics and Biopharmaceutics
MedicineBiotechnologyPharmaceutical Science
2012English

Enhancement of Anticancer Activity in Antineovascular Therapy Is Based on the Intratumoral Distribution of the Active Targeting Carrier for Anticancer Drugs

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2006English

A Further Strategy to Combat the High Price of Anticancer Drugs

Nature Reviews Clinical Oncology
Oncology
2017English

In Silico Prescription of Anticancer Drugs to Cohorts of 28 Tumor Types Reveals Targeting Opportunities

Cancer Cell
Cancer ResearchOncologyCell Biology
2015English

Drugs for the Treatment of Metabolic Bone Diseases

British Journal of Clinical Pharmacology
Pharmacology
2019English

Mechanistic and Structural Basis for Inhibition of Copper Trafficking by Platinum Anticancer Drugs

English

Direct Inhibition of STAT Signaling by Platinum Drugs Contributes to Their Anti-Cancer Activity

Oncotarget
Oncology
2017English

Effect of Bisphosphonate on Osteoclast of Bone

Forensic Medicine and Anatomy Research
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy